EUVIMEDEUVIMED entdecken
Multizentrische Studie

Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors

Mustafa Gürbüz iD, Deniz Tural, Timuçin Çil, Hacer Demir, Osman Köstek iD, Özlem Nuray Sever, İmdat Eroğlu iD, İzzet Doğan iD, Mehmet Ali Nahit Şendur iD, Çağatay Arslan iD, Emre Akar iD, Elif Berna Köksoy und 13 weitere

JCO Global Oncology · 2026-03 · 12 (3)

DOI: 10.1200/go-25-00234 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JCO Global Oncology, 2026-03. Verfasst von Mustafa Gürbüz und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Başkent University Faculty of Medicine, Adana, Turkey. Hauptthemen laut MEDLINE: Neoplasms, Hepatitis B, Hepatitis C, Virus Activation. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are clinically significant in patients with cancer, as chemotherapy can trigger viral reactivation, leading to liver failure, treatment interruption, or death. Despite this risk, routine viral screening in patients with solid tumors remains inconsistent across institutions and guidelines. The purpose is to determine the frequency of viral screening and the prevalence of HBV, HCV, and HIV infections—and to assess the rate of viral reactivation—in a large cohort of newly diagnosed adult patients with cancer receiving chemotherapy. MATERIALS AND METHODS A retrospective, multicenter cohort study was conducted across 15 oncology centers in Turkey. Data from 15,942 adults with solid tumors receiving parenteral chemotherapy between January 2018 and December 2022 were analyzed. Patients with primary liver cancer or those receiving non-immunosuppressive therapies were excluded. RESULTS Among 15,942 patients (median age, 58 years [range, 16-94]; 51.4% male), hepatitis B surface antigen (HBsAg) testing was performed in 90.3%, anti-HCV in 71.7%, and anti-HIV in 64.0%. HBV infection was identified in 4.5% (n = 645), with only 42.9% receiving antiviral prophylaxis. HBV reactivation occurred in 4.0% of HBsAg-positive patients (n = 26). Anti-HCV positivity was found in 0.4% (n = 46), of whom 17.4% had detectable HCV RNA and received treatment. HIV infection was rare (0.06%; n = 6), and no cases of viral reactivation were observed. CONCLUSION This large multicenter study highlights persistent gaps in viral screening and prophylaxis among patients with solid tumors. Despite lower HBV reactivation rates—likely due to partial prophylaxis—preventable complications still occurred. Despite increases in vaccination and prophylaxis, reactivation rates remain a significant problem. Standardized national protocols for prechemotherapy viral screening and timely antiviral therapy are essential to improve patient safety and treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHepatitis BHepatitis CVirus ActivationAntineoplastic AgentsHumansFemaleMaleAdultMiddle AgedPrevalenceRetrospective StudiesAgedAged, 80 and overAdolescentYoung AdultHepatitis B virus

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medical Oncology, Başkent University Faculty of Medicine, Adana, Turkey.
  • Department of Medical Oncology, Koç University School of Medicine, Istanbul, Turkey.
  • Department of Medical Oncology, University of Health Sciences, Adana City Training and Research Hospital, Adana, Turkey.
  • Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar, Turkey.
  • Department of Medical Oncology, Marmara University Faculty of Medicine, İstanbul, Turkey.
  • Department of Medical Oncology, Medical Park Bahçelievler Hospital, İstanbul, Turkey.

ORCID-Profile: Mustafa Gürbüz, Osman Köstek, İmdat Eroğlu, İzzet Doğan, Mehmet Ali Nahit Şendur, Çağatay Arslan, Emre Akar, İsmail Beypınar, İrfan Çiçin, Şahin Laçin, Didem Taştekin, Lokman Koral, Yüksel Ürün

Zitieren

APA

Gürbüz, M., Tural, D., Çil, T., Demir, H., Köstek, O., Sever, Ö. N., Eroğlu, İ., Doğan, İ., Şendur, M. A. N., Arslan, Ç., Akar, E., Köksoy, E. B., Beypınar, İ., Çiçin, İ., Laçin, Ş., Taştekin, D., Utkan, G., Koral, L., Paydaş, S., …, & Ürün, Y. (2026). Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors. JCO Global Oncology, 12(3). https://doi.org/10.1200/go-25-00234

Vancouver

Gürbüz M, Tural D, Çil T, Demir H, Köstek O, Sever ÖN, et al. Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors. JCO Global Oncology. 2026;12(3). doi:10.1200/go-25-00234

BibTeX
@article{Grbz2026,
  author = {Gürbüz, Mustafa and Tural, Deniz and Çil, Timuçin and Demir, Hacer and Köstek, Osman and Sever, Özlem Nuray and Eroğlu, İmdat and Doğan, İzzet and Şendur, Mehmet Ali Nahit and Arslan, Çağatay and Akar, Emre and Köksoy, Elif Berna and Beypınar, İsmail and Çiçin, İrfan and Laçin, Şahin and Taştekin, Didem and Utkan, Güngör and Koral, Lokman and Paydaş, Semra and Dede, İsa and Bayhan, Ahmet Ziya and Kaplan, Muhammet Ali and Tanrıverdi, Özgür and Kılıçkap, Saadettin and Ürün, Yüksel},
  title = {Prevalence and Reactivation of Hepatitis B and C in Patients Undergoing Chemotherapy for Solid Tumors},
  journal = {JCO Global Oncology},
  year = {2026},
  volume = {12},
  number = {3},
  doi = {10.1200/go-25-00234}
}
Kostenlos starten →